Canada Approves Shire's Elaprase
Posted on: Thursday, 14 June 2007, 12:14 CDT
Shire said Thursday Health Canada approved Elaprase for treating Hunter syndrome, a rare genetic disorder that can be life-threatening.
Elaprase, an enzyme replacement therapy that is given as weekly infusions, has previously been approved in the United States and Europe.
Health Canada's approval of Elaprase is another important step in bringing this much-needed treatment to Hunter syndrome patients around the world, said Matthew Emmens, Shire's chief executive officer.
Approximately 291 patients worldwide are being treated with Elaprase, which replaces the lysosomal enzyme iduronate-2-sulfatase. Hunter syndrome patients have insufficient levels of this enzyme, which can lead to organ malfunction.
Shire estimates there are about 2,000 Hunter syndrome patients worldwide in areas where reimbursement may be possible.
Source: United Press International
Related Articles
- Shire's Elaprase Gets Approval in Mexico for Hunter Syndrome
- Shire's ELAPRASE(R) (Idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
- Shire's ELAPRASE(TM) (Idursulfase) Approved By Health Canada for Treatment of Hunter Syndrome
- Shire Gets Approval for First Hunter Syndrome Therapy
- The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
- Shire Hunter Syndrome Drug Gets FDA OK
- Shire's ELAPRASE(TM) (Idursulfase) Approved By the Food and Drug Administration (FDA) for Hunter Syndrome
- Shire Files Idursulfase With EMEA for Treatment of Hunter Syndrome
- Shire Files Elaprase(TM) (Idursulfase) With the FDA for the Treatment of Hunter Syndrome
- Shire Presents Positive Results of Hunter Syndrome Pivotal Clinical Trial at The American Society of Human Genetics Annual Meeting
 |
 |
User Comments (0)
RSS Feeds